Title : Unveiling the binding interactions of selected antimalarial drugs with major plasma transporter
Abstract:
Using a variety of spectroscopic methods and in silico analysis, the binding interactions between three antimalarial medications, mefloquine (MEF), lumefantrine (LUM), and pyrimethamine (PYR) and the primary plasma transporter, human serum albumin (HSA) were examined. Molecular docking analysis designated Sudlow’s Site I, located in subdomain IIA of HSA, as the preferred binding site of these drugs, which was also supported by competitive drug displacement results. The quenching of protein (HSA) fluorescence induced by these drugs was characterized as static quenching, thus suggesting drug-HSA complex formation. This was also supported by UV-Vis absorption spectral results. Moderate binding affinity between these drugs and HSA was revealed from the association constant, Ka values (1.32-7.27 ´ 104 M-1). Both molecular docking results and thermodynamic data predicted noncovalent forces, viz., hydrogen bonds, hydrophobic and van der Waals forces, to stabilize drug-HSA complexes. Smaller modifications to secondary and tertiary structures as well as microenvironmental alterations surrounding protein fluorophores were also brought about by drug binding.
Audience Take Away Notes:
- The audience will learn about the characteristics of antimalarial drug-HSA interaction
- It will reflect the efficacy of these drugs in the presence of other drugs, which bind to the same site on HSA
- Drug-drug interactions can be studied using the binding characteristics of antimalarial drugs